Q1 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology LeqvioⓇ - siRNA (regulation of LDL-C) NCT05030428 VICTORION-2P (CKJX839B12302) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Appendix Innovation: Clinical trials Neuroscience Oncology References Leqvio® - siRNA (regulation of LDL-C) NCT05739383 VICTORION-1P (CKJX839D12302) CVRR (Primary prevention) Phase 3 Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C Indication Phase Phase 3 Patients 14000 15000 1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) Primary Outcome Measures Arm 1: Experimental Inclisiran sodium, Subcutaneous injection Arm 2: Placebo Comparator, Placebo Subcutaneous injection Arms Intervention Participants with established cardiovascular disease (CVD) Readout 2027 Milestone(s) Publication TBD 50 Investor Relations | Q1 2023 Results Target Patients Abbreviations Other Time to the first occurrence of 4P-MACE 4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization Arm 1 Experimental: Inclisiran Sodium 300mg, subcutaneous injection in pre-filled syringe Arm 2 Placebo High-risk primary prevention patients Readout Milestone(s) Publication 2029 TBD NOVARTIS | Reimagining Medicine

View entire presentation